Liquidia Advances with YUTREPIA After Court Ruling

Liquidia Technologies ( (LQDA) ) has shared an announcement.

On June 2, 2025, Liquidia Corporation announced that the U.S. District Court for the Middle District of North Carolina denied United Therapeutics Corporation’s motion for a preliminary injunction and temporary restraining order against Liquidia. This decision, made on May 30, 2025, allows Liquidia to proceed with the commercialization of YUTREPIA™ (treprostinil) inhalation powder, which was approved by the FDA on May 23, 2025, for treating PAH and PH-ILD. The court’s ruling clears the way for Liquidia to make its first commercial shipment of YUTREPIA, marking a significant milestone in the company’s operations and positioning it to offer a new therapeutic alternative in the market.

The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.

Spark’s Take on LQDA Stock

According to Spark, TipRanks’ AI Analyst, LQDA is a Neutral.

Liquidia Technologies’ stock score reflects the company’s financial challenges and mixed technical indicators, balanced by strategic advancements and FDA approval of YUTREPIA. While the approval is a major milestone, financial instability and legal uncertainties restrain the overall score.

To see Spark’s full report on LQDA stock, click here.

More about Liquidia Technologies

Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company utilizes its proprietary PRINT® Technology to develop and commercialize products such as YUTREPIA™ (treprostinil) inhalation powder, approved for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia also markets generic Treprostinil Injection for PAH and is developing L606, a sustained-release formulation of treprostinil.

Average Trading Volume: 1,406,589

Technical Sentiment Signal: Buy

Current Market Cap: $1.28B

See more insights into LQDA stock on TipRanks’ Stock Analysis page.